Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Buckner

Showing results (201-210 of 255) with videos related to

Pageof 26
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 17, 1998
Phase II trial of nitrogen mustard, vincristine, and procarbazine in patients with recurrent glioma: North Central Cancer Treatment Group resultsE Galanis, J C Buckner, P A Burch, et al.
Journal of Neuro-Oncology|September 16, 2005
Prospective study of quality of life in adults with newly diagnosed high-grade gliomasPaul D Brown, Karla V Ballman, Teresa A Rummans, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 22, 2006
Phase III trial of carmustine and cisplatin compared with carmustine alone and standard radiation therapy or accelerated radiation therapy in patients with glioblastoma multiforme: North Central Cancer Treatment Group 93-72-52 and Southwest Oncology Group 9503 TrialsJan C Buckner, Karla V Ballman, John C Michalak, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 9, 2013
Phase II study of bevacizumab in combination with sorafenib in recurrent glioblastoma (N0776): a north central cancer treatment group trialEvanthia Galanis, S Keith Anderson, Jackie M Lafky, et al.
Journal of the National Cancer Institute|August 16, 2001
PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiformeJ S Smith, I Tachibana, S M Passe, et al.
Journal of Neuro-Oncology|November 18, 2008
Evaluation of MGMT promoter methylation status and correlation with temozolomide response in orthotopic glioblastoma xenograft modelGaspar J Kitange, Brett L Carlson, Ann C Mladek, et al.
International Journal of Oncology|July 31, 1999
Tumor suppressor gene alterations in malignant gliomas: histopathological associations and prognostic evaluationC D James, E Galanis, L Frederick, et al.
International Journal of Radiation Oncology, Biology, Physics|April 20, 2004
Importance of baseline mini-mental state examination as a prognostic factor for patients with low-grade gliomaPaul D Brown, Jan C Buckner, Judith R O'Fallon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 28, 2003
Effects of radiotherapy on cognitive function in patients with low-grade glioma measured by the folstein mini-mental state examinationPaul D Brown, Jan C Buckner, Judith R O'Fallon, et al.
Journal of Neuro-Oncology|June 6, 2019
Correction to: Phase I-II trial of imatinib mesylate (Gleevec; STI571) in treatment of recurrent oligodendroglioma and mixed oligoastrocytoma. North central cancer treatment group study N0272 (ALLIANCE/NCCTG)Kurt A Jaeckle, S K Anderson, Erin L Twohy, et al.
Pageof 26

Showing results (201-210 of 255) with videos related to

Sort By:
Pageof 26
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 17, 1998
Phase II trial of nitrogen mustard, vincristine, and procarbazine in patients with recurrent glioma: North Central Cancer Treatment Group resultsE Galanis, J C Buckner, P A Burch, et al.
Journal of Neuro-Oncology|September 16, 2005
Prospective study of quality of life in adults with newly diagnosed high-grade gliomasPaul D Brown, Karla V Ballman, Teresa A Rummans, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 22, 2006
Phase III trial of carmustine and cisplatin compared with carmustine alone and standard radiation therapy or accelerated radiation therapy in patients with glioblastoma multiforme: North Central Cancer Treatment Group 93-72-52 and Southwest Oncology Group 9503 TrialsJan C Buckner, Karla V Ballman, John C Michalak, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 9, 2013
Phase II study of bevacizumab in combination with sorafenib in recurrent glioblastoma (N0776): a north central cancer treatment group trialEvanthia Galanis, S Keith Anderson, Jackie M Lafky, et al.
Journal of the National Cancer Institute|August 16, 2001
PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiformeJ S Smith, I Tachibana, S M Passe, et al.
Journal of Neuro-Oncology|November 18, 2008
Evaluation of MGMT promoter methylation status and correlation with temozolomide response in orthotopic glioblastoma xenograft modelGaspar J Kitange, Brett L Carlson, Ann C Mladek, et al.
International Journal of Oncology|July 31, 1999
Tumor suppressor gene alterations in malignant gliomas: histopathological associations and prognostic evaluationC D James, E Galanis, L Frederick, et al.
International Journal of Radiation Oncology, Biology, Physics|April 20, 2004
Importance of baseline mini-mental state examination as a prognostic factor for patients with low-grade gliomaPaul D Brown, Jan C Buckner, Judith R O'Fallon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 28, 2003
Effects of radiotherapy on cognitive function in patients with low-grade glioma measured by the folstein mini-mental state examinationPaul D Brown, Jan C Buckner, Judith R O'Fallon, et al.
Journal of Neuro-Oncology|June 6, 2019
Correction to: Phase I-II trial of imatinib mesylate (Gleevec; STI571) in treatment of recurrent oligodendroglioma and mixed oligoastrocytoma. North central cancer treatment group study N0272 (ALLIANCE/NCCTG)Kurt A Jaeckle, S K Anderson, Erin L Twohy, et al.
Pageof 26